根据程序性死亡配体1表达和免疫浸润对肿瘤免疫微环境分类可预测晚期非小细胞肺癌患者对免疫治疗联合化疗的应答
基于ORIENT-11研究的RNA测序和免疫组化数据优化肿瘤免疫微环境(TIME)分类模型,以PD-L1 mRNA表达和ESTIMATE免疫评分定义分型。仅高免疫评分且高PD-L1 mRNA表达的II型亚组从免疫联合化疗中显著获益,PFS HR=0.12、OS HR=0.27。
要点
- 以PD-L1 mRNA表达和ESTIMATE免疫评分优化TIME分型。
- 仅II型(高免疫评分且高PD-L1 mRNA)从联合治疗显著获益。
- 联合组II型中位PFS和OS均未达到,其余三型PFS相似。
核心结论
- 仅PD-L1高表达且免疫浸润高的晚期NSCLC患者在一线化疗联合免疫治疗中获益。
- 缺乏PD-L1表达或免疫浸润的患者,单用化疗可能是更好的选择,以避免不必要的毒性和经济负担。
研究设计与样本
- 基于ORIENT-11研究的RNA测序和免疫组化数据,优化TIME分类模型并评估其对免疫联合化疗疗效的预测价值。
主要发现
- PD-L1 mRNA表达和ESTIMATE法计算的免疫评分是免疫联合化疗疗效的最强预测因子。
- 联合治疗与单用化疗比较,仅高免疫评分且高PD-L1 mRNA表达的II型亚组与PFS改善显著相关(HR=0.12,95%CI:0.06-0.25,p<0.001)。
- 同一II型亚组与OS改善显著相关(HR=0.27,95%CI:0.13-0.55,p<0.001)。
- 联合组中II型亚组生存时间明显更长,中位PFS和OS均未达到,其余三个亚组PFS相似。
- 化疗组中生存结局与TIME亚型无明显关联。
关键数值与推荐
- TIME优化分型以PD-L1 mRNA表达和ESTIMATE免疫评分定义。
- II型亚组定义为高免疫评分且高PD-L1 mRNA表达。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: According to mechanisms of adaptive immune resistance, tumor immune microenvironment (TIME) is classified into four types: (1) programmed death-ligand 1 (PD-L1)-negative and tumor-infiltrating lymphocyte (TIL)-negative (type I); (2) PD-L1-positive and TIL-positive (type II); (3) PD-L1-negative and TIL-positive (type III); and (4) PD-L1-positive and TIL-negative (type IV). However, the relationship between the TIME classification model and immunotherapy efficacy has not been validated by any large-scale randomized controlled clinical trial among patients with advanced NSCLC. METHODS: On the basis of RNA-sequencing and immunohistochemistry data from the ORIENT-11 study, we optimized the TIME classification model and evaluated its predictive value for the efficacy of immunotherapy plus chemotherapy. RESULTS: PD-L1 mRNA expression and immune score calculated by the ESTIMATE method were the strongest predictors for the efficacy of immunotherapy plus chemotherapy. Therefore, they were determined as the optimized definition of the TIME classification system. When compared between combination therapy and chemotherapy alone, only the type II subpopulation with high immune score and high PD-L1 mRNA expression was significantly associated with improved progression-free survival (PFS) (hazard ratio = 0.12, 95% confidence interval: 0.06-0.25, p < 0.001) and overall survival (hazard ratio = 0.27, 95% confidence interval: 0.13-0.55, p < 0.001). In the combination group, the type II subpopulation had a much longer survival time, not even reaching the median PFS or overall survival, but the other three subpopulations were susceptible to having similar PFS. In the chemotherapy group, there was no marked association between survival outcomes and TIME subtypes. CONCLUSIONS: Only patients with both high PD-L1 expression and high immune infiltration could benefit from chemotherapy plus immunotherapy in first-line treatment of advanced NSCLC. For patients lacking either PD-L1 expression or immune infiltration, chemotherapy alone might be a better treatment option to avoid unnecessary toxicities and financial burdens.
引用
- Sun D, Liu J, Zhou H, et al. Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. J Thorac Oncol. 2023. PMID: 36948245. doi:10.1016/j.jtho.2023.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。